SCHEMBL24221837

SCHEMBL24221837

Bc1c(B)c(B)c2c(C(=O)c3cc(Br)c(OC(C)=O)c(Br)c3)c(CC)oc2c1B

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 3/20 0.47
▸ TTR P02766 7/20 0.42
▸ SLC22A12 Q96S37 9/20 0.42
▸ NR1H4 Q96RI1 4/20 0.41
▸ EYA3 Q99504 4/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ EYA2 O00167 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ ABCC4 O15439 1/20 0.41
▸ PLIN1 O60240 1/20 0.41
▸ NR1I2 O75469 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ ABCB11 O95342 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ ALB P02768 1/20 0.41
▸ ESR1 P03372 1/20 0.41
▸ NR3C1 P04150 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ PGR P06401 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24102976 0.94 CYP2C19 (0.46) CYP2C19TTRSLC22A12NR1H4EYA3
SCHEMBL22680778 0.88 CYP2C19 (0.60) CYP2C19TTRSLC22A12NR1H4EYA3
SCHEMBL22680479 0.86 TTR (0.43) CYP2C19TTRSLC22A12NR1H4EYA3
SCHEMBL22680772 0.83 SLC22A12 (0.42) CYP2C19TTRSLC22A12NR1H4EYA3
SCHEMBL22072519 0.83 TTR (0.46) CYP2C19TTRSLC22A12NR1H4EYA3
SCHEMBL24103740 0.81 CYP2C19 (0.32) CYP2C19NR1H4EYA3
SCHEMBL22680588 0.79 SLC22A12 (0.43) CYP2C19TTRSLC22A12NR1H4EYA3
SCHEMBL25815944 0.79 SLC22A12 (0.56) CYP2C19TTRSLC22A12NR1H4EYA3
SCHEMBL26211986 0.79 SLC22A12 (0.54) CYP2C19TTRSLC22A12NR1H4EYA3
SCHEMBL25815357 0.76 SLC22A12 (0.52) CYP2C19TTRSLC22A12NR1H4EYA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ARTHROSI THERAPEUTICS, INC. 2023-07-13 — — US disclosed
US-20220023251-A1 METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA ARTHROSI THERAPEUTICS, INC. 2022-01-27 — — US disclosed
US-20220024889-A1 CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA ARTHROSI THERAPEUTICS, INC. 2022-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024889-A1 CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA CYP27A1, CYP24A1, CYP27B1 CYP2C19 649/4885TTR 117/4885SLC22A12 854/4885
US-20220023251-A1 METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA CYP27B1, XDH, CYP27A1 CYP2C19 660/4885TTR 189/4885SLC22A12 830/4885
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ATP6V1B1, REN, CYP27B1 CYP2C19 826/4885TTR 201/4885SLC22A12 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback